Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug aims to tame rare blood disorder flares

NCT ID NCT04191304

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 study tests whether benralizumab, a biologic injection given every 4 weeks, can reduce flares in people with hypereosinophilic syndrome (HES), a rare condition where too many eosinophils cause organ damage. About 134 patients aged 12 and older will receive either benralizumab or a placebo for 24 weeks, followed by an open-label extension where everyone gets the drug. The main goal is to see how long it takes for a flare to occur.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Benralizumab (a biologic drug given as an injection every 4 weeks)

What this could lead to

If it works, this could provide a new treatment option to reduce flares and control symptoms for people with hypereosinophilic syndrome.

What could go wrong

This is a Phase 3 trial, but results are not yet final. The drug may not work better than placebo, and side effects are possible. The study is also relatively small (134 participants).

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPEREOSINOPHILIC SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypereosinophilic syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPEREOSINOPHILIC SYNDROME

Contacts and locations

Locations

  • Research Site

    La Jolla, California, 92037, United States

  • Research Site

    Atlanta, Georgia, 30324, United States

  • Research Site

    Bethesda, Maryland, 20892, United States

  • Research Site

    Ann Arbor, Michigan, 48105, United States

  • Research Site

    Durham, North Carolina, 27705, United States

  • Research Site

    Cleveland, Ohio, 44106, United States

  • Research Site

    Columbus, Ohio, 43212, United States

  • Research Site

    Salt Lake City, Utah, 84112, United States

  • Research Site

    Rosario, 2000, Argentina

  • Research Site

    Innsbruck, 6020, Austria

  • Research Site

    Brussels, 1070, Belgium

  • Research Site

    Edegem, 2650, Belgium

  • Research Site

    Chengdu, 610041, China

  • Research Site

    Tianjin, 300020, China

  • Research Site

    Xiamen, 361015, China

  • Research Site

    Zhengzhou, 450008, China

  • Research Site

    København Ø, 2100, Denmark

  • Research Site

    Lille, 59037, France

  • Research Site

    Pessac, 33604, France

  • Research Site

    Strasbourg, 67091, France

  • Research Site

    Suresnes, 92151, France

  • Research Site

    Toulouse, 31059, France

  • Research Site

    Hanover, 30625, Germany

  • Research Site

    Kirchheim, 73230, Germany

  • Research Site

    Mannheim, 68167, Germany

  • Research Site

    Ahmedabad, 380013, India

  • Research Site

    Ajmer, 305001, India

  • Research Site

    Delhi, 110029, India

  • Research Site

    Haifa, 34362, Israel

  • Research Site

    Holon, 58100, Israel

  • Research Site

    Jerusalem, 91120, Israel

  • Research Site

    Kfar Saba, 44218, Israel

  • Research Site

    Petah Tikva, 49100, Israel

  • Research Site

    Ramat Gan, 5265601, Israel

  • Research Site

    Rehovot, 76100, Israel

  • Research Site

    Tel Aviv, 64239, Israel

  • Research Site

    Bologna, 40138, Italy

  • Research Site

    Chiba, 260-0852, Japan

  • Research Site

    Hamamatsu, 431-3192, Japan

  • Research Site

    Ichikawa-shi, 272-8516, Japan

  • Research Site

    Kawasaki-shi, 211-8510, Japan

  • Research Site

    Nishinomiya-shi, 663-8501, Japan

  • Research Site

    Osaka, 530-8480, Japan

  • Research Site

    Sendai, 980-8574, Japan

  • Research Site

    Rotterdam, 3015 GD, Netherlands

  • Research Site

    Chęciny, 26-060, Poland

  • Research Site

    Gdansk, 80-214, Poland

  • Research Site

    Lodz, 90-153, Poland

  • Research Site

    Seoul, 5505, South Korea

  • Research Site

    Santander, 39010, Spain

  • Research Site

    London, W2 1NY, United Kingdom